Kulsum Bano, MD
Hematology & Oncology · Charlotte, NCNPI 1114378775
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $131 of the $203 with a category attached, or 64.6%. 4 manufacturers reported payments, led by AstraZeneca at 49.2% of the total. Reporting peaked in 2022 at $100 and has fallen 68.7% since, to $31 in 2023. That places this record below the midpoint for hematology & oncology clinicians in NC, where the typical reported total is $1,703.
Across 4 payments — averaging $50.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$100
- Amgen$72
- Seagen Inc.$18
- GSK$13
What the payments were for
- Food & beverage$13165%
- Education$7235%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $100 |
| Amgen | 1 | $72 |
| Seagen Inc. | 1 | $18 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$100
How this compares
$203 in reported general payments places this provider in the 20th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 13 | $223,909 |
| EliquisApixaban | 40 | $26,924 |
| Anastrozole | 113 | $2,589 |
| Letrozole | 52 | $831 |
| Dexamethasone | 13 | $326 |
| Ondansetron Hcl | 34 | $302 |
| Gabapentin | 19 | $301 |
| Potassium Chloride | 23 | $285 |
| Hydroxyurea | 31 | $267 |
| Omeprazole | 19 | $236 |
| Duloxetine Hcl | 15 | $203 |
| Warfarin Sodium | 19 | $180 |
| Prochlorperazine Maleate | 17 | $155 |
| Acyclovir | 24 | $149 |
| Ondansetron OdtOndansetron | 15 | $127 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Charlotte
- Shelbi AtrashCharlotte$994K
- Nasfat ShehadehCharlotte$68K
- Jennifer AtlasCharlotte$59K
- Joseph MerrimanCharlotte$50K
- Justin FavaroCharlotte$33K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.